Moreover, current treatments for DN, including renin-angiotensin-aldosterone system inhibitors and sodium-glucose cotransporter 2 inhibitors, have shown promise in delaying disease progression, partly through the suppression of O-GlcNAc modifications (15, 16). The gene discussed is SLC5A2; the disease is liver dysplastic nodule.